Catalent (CTLT) to Acquire MaSTherCell Global for $315 Million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- Netflix raises prices in Germany and Austria, Citi comments
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Catalent (CTLT) Prices Common Share Offering for Gross Proceeds of Approx. $500M
February 4, 2020 5:39 AM ESTCatalent, Inc. (Catalent) (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced the pricing of an underwritten public offering (the Offering) of shares of its common stock, which is expected to result in gross proceeds of approximately $500 million, before deducting estimated offering expenses. The underwriters may offer the shares of... More
Catalent (CTLT) Tops Q2 EPS by 1c, Revenues Beat; Raises FY20 Revenue Guidance Above Consensus
February 3, 2020 7:32 AM ESTCatalent (NYSE: CTLT) reported Q2 EPS of $0.45, $0.01 better than the analyst estimate of $0.44. Revenue for the quarter came in at $721.4 million versus the consensus estimate of $698.52 million.
Q2'20 revenue of $721.4 million increased 16% as-reported, or 17% in constant currency, from Q2'19.Accelerated growth in the Biologics segment. Solid organic growth in the Softgel and Oral Technologies and Clinical Supply Services segments more than offset decline in the Oral and Specialty Delivery segment.Announcing further expansion of Biologics footprint with agreement to acquire MaSTherCell, a leading cell therapy development and manufacturing... More